Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Miquel Duran-Frigola

Showing results (1-10 of 54) with videos related to

Pageof 6
Sort By:
Chemistry & Biology|April 23, 2013
Analysis of chemical and biological features yields mechanistic insights into drug side effectsMiquel Duran-Frigola, Patrick Aloy
Genome Medicine|January 31, 2012
Recycling side-effects into clinical markers for drug repositioningMiquel Duran-Frigola, Patrick Aloy
Nature Communications|December 2, 2014
A chemo-centric view of human health and diseaseMiquel Duran-Frigola, David Rossell, Patrick Aloy
ACS Infectious Diseases|August 2, 2024
Infectious Disease Research Laboratories in Africa Are Not Using AI Yet─Large Language Models May Facilitate AdoptionGemma Turon, Dhanshree Arora, Miquel Duran-Frigola
Chemistry & Biology|May 28, 2013
Structural systems pharmacology: the role of 3D structures in next-generation drug developmentMiquel Duran-Frigola, Roberto Mosca, Patrick Aloy
Molecular Cancer|April 17, 2015
Drug sensitivity in cancer cell lines is not tissue-specificSamira Jaeger, Miquel Duran-Frigola, Patrick Aloy
Genome Medicine|March 28, 2019
Encircling the regions of the pharmacogenomic landscape that determine drug responseAdrià Fernández-Torras, Miquel Duran-Frigola, Patrick Aloy
Bioinformatics (Oxford, England)|November 9, 2014
IntSide: a web server for the chemical and biological examination of drug side effectsTeresa Juan-Blanco, Miquel Duran-Frigola, Patrick Aloy
Journal of the American Chemical Society|January 27, 2023
Advancing Targeted Protein Degradation via Multiomics Profiling and Artificial IntelligenceMiquel Duran-Frigola, Marko Cigler, Georg E Winter
Journal of Molecular Biology|April 8, 2018
Rationalizing Drug Response in Cancer Cell LinesTeresa Juan-Blanco, Miquel Duran-Frigola, Patrick Aloy
Pageof 6

Showing results (1-10 of 54) with videos related to

Sort By:
Pageof 6
Chemistry & Biology|April 23, 2013
Analysis of chemical and biological features yields mechanistic insights into drug side effectsMiquel Duran-Frigola, Patrick Aloy
Genome Medicine|January 31, 2012
Recycling side-effects into clinical markers for drug repositioningMiquel Duran-Frigola, Patrick Aloy
Nature Communications|December 2, 2014
A chemo-centric view of human health and diseaseMiquel Duran-Frigola, David Rossell, Patrick Aloy
ACS Infectious Diseases|August 2, 2024
Infectious Disease Research Laboratories in Africa Are Not Using AI Yet─Large Language Models May Facilitate AdoptionGemma Turon, Dhanshree Arora, Miquel Duran-Frigola
Chemistry & Biology|May 28, 2013
Structural systems pharmacology: the role of 3D structures in next-generation drug developmentMiquel Duran-Frigola, Roberto Mosca, Patrick Aloy
Molecular Cancer|April 17, 2015
Drug sensitivity in cancer cell lines is not tissue-specificSamira Jaeger, Miquel Duran-Frigola, Patrick Aloy
Genome Medicine|March 28, 2019
Encircling the regions of the pharmacogenomic landscape that determine drug responseAdrià Fernández-Torras, Miquel Duran-Frigola, Patrick Aloy
Bioinformatics (Oxford, England)|November 9, 2014
IntSide: a web server for the chemical and biological examination of drug side effectsTeresa Juan-Blanco, Miquel Duran-Frigola, Patrick Aloy
Journal of the American Chemical Society|January 27, 2023
Advancing Targeted Protein Degradation via Multiomics Profiling and Artificial IntelligenceMiquel Duran-Frigola, Marko Cigler, Georg E Winter
Journal of Molecular Biology|April 8, 2018
Rationalizing Drug Response in Cancer Cell LinesTeresa Juan-Blanco, Miquel Duran-Frigola, Patrick Aloy
Pageof 6